Table 4. Summary of efficacy results for patients receiving high-dosage ICS/LABA with baseline blood eosinophil counts ≥ 300 cells/μL in the Korean and overall SIROCCO trial populations (benralizumab vs. placebo).

	Korean patients in SIROCCO*		SIROCCO overall patient population15
	Benralizumab Q4W (n = 28)	Benralizumab Q8W (n = 30)	Benralizumab Q4W (n = 275)	Benralizumab Q8W (n = 267)
Reduction in annual exacerbation rate (%)	↓70‡	↓85†	↓45†	↓51†
Increase in prebronchodilator FEV1 (L)	↑0.270§	↑0.362‡	↑0.106§	↑0.159†
Change in total asthma symptom score	↓0.28	↑0.07	↓0.08	↓0.25§

FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroids; LABA, long-acting β₂-agonists; Q4W, every 4 weeks; Q8W, every 8 weeks (first three doses Q4W).

^*All P values are nominal; ^†P value < 0.001; ^‡P value ≥ 0.001 to ≤ 0.01; ^§P value > 0.01 to ≤ 0.05.